The size of the North America Animal Parasiticides Market has been calculated at USD 2.29 billion in 2022. It is forecasted to be growing at a CAGR of 5.7% and worth USD 3.03 billion by 2027.
The market shows a decent amount of potential for growth during the forecasting period. It is expected to expand with the development of animal healthcare. Animal parasiticides are the medicines used for animals to eradicate the parasites present on animals. These substances generally stay inert and are formed by mixing different ingredients with each other. Most ingredients in a parasiticide have similar kind of chemical structures and thus have many common characteristics in them. They are often grouped according to their chemical structure. The animal parasiticides are regarded as very important for the protection of animals from parasitic diseases.
An increase in spending on the healthcare of animals, increasing population with pet animals and growing concern for animal products are considered to be the driving factors for the growth of the North America Animal Parasiticides market.
However, the increased popularity of vegetarian and vegan lifestyles combined with strict restrictions on the sanctioning of animal parasiticides are some constraints for the growth of the North America animal parasiticides market.
This research report on the North America Animal Parasiticides Market has been segmented and sub-segmented into the following categories:
By Animal type:
Some of the major companies dominating the North America animal parasiticides market profiled in the report are Sanofi S.A. (Merial), Ceva Sante Animale, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org